A prospective Phase II study of Isatuximab Rescue for Inadequate response to Lenalidomide and Dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma
Latest Information Update: 22 Jan 2024
At a glance
- Drugs Isatuximab (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms IRIL
Most Recent Events
- 12 Dec 2023 Interim Analysis (n=42) of data from June 2019 to June 2021, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 14 Dec 2021 Interim Analysis of the Phase II Iril Study presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 03 Jul 2019 Status changed from not yet recruiting to recruiting.